Clinicopathologic analysis of programmed cell death-1 and programmed cell death-ligand 1 and 2 expressions in pulmonary adenocarcinoma: Comparison with histology and driver oncogenic alteration status

Modern Pathology

Volumn 28, Issue 9, 2015, Pages 1154-1166

  Koh, Jaemoon ^a   Go, Heounjeong ^b   Keam, Bhumsuk ^a   Kim, Moon Young ^a   Nam, Soo Jeong ^a   Kim, Tae Min ^a   Lee, Se Hoon ^a   Min, Hye Sook ^c   Kim, Young Tae ^a   Kim, Dong Wan ^a   Jeon, Yoon Kyung ^a   Chung, Doo Hyun ^a,d  

^a Seoul National University Hospital   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c Seoul National University   (South Korea)

^d Seoul National University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2; SCATTER FACTOR RECEPTOR; CD274 PROTEIN, HUMAN; PDCD1 PROTEIN, HUMAN; PDCD1LG2 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

ADULT; ARTICLE; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; DISEASE FREE SURVIVAL; FEMALE; GENE MUTATION; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; LUNG ADENOCARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SMOKING; TISSUE MICROARRAY; TUMOR ASSOCIATED LEUKOCYTE; TUMOR VOLUME; ADENOCARCINOMA; COMPARATIVE STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; KAPLAN MEIER METHOD; LUNG TUMOR; METABOLISM; PATHOLOGY;

ADENOCARCINOMA; ANTIGENS, CD274; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; PROGRAMMED CELL DEATH 1 LIGAND 2 PROTEIN; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 84940722192     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2015.63     Document Type: Article

References (49)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
2. Reck M, Heigener DF, Mok T et al. Management of nonsmall-cell lung cancer: recent developments. Lancet 2013;382:709-719.
3. Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-957.
4. Shaw AT, Kim DW, Nakagawa K et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368:2385-2394.
5. Ohashi K, Maruvka YE, Michor F et al. Epidermal growth factor receptor tyrosine kinase inhibitorresistant disease. J Clin Oncol 2013;31:1070-1080.
6. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12: 252-264.
7. Nishimura H, Honjo T. PD-1: An inhibitory immunoreceptor involved in peripheral tolerance. Trends Immunol 2001;22:265-268.
8. Okazaki T, Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol 2007;19: 813-824.
9. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996;271:1734-1736.
10. Ott PA, Hodi FS, C Robert. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res 2013;19:5300-5309.
11. Iwai Y, Ishida M, Tanaka Y et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 2002;99:12293-12297.
12. Rozali EN, Hato SV, Robinson BW et al. Programmed death ligand 2 in cancer-induced immune suppression. Clin Dev Immunol 2012;2012:656340.
13. Zielinski C, Knapp S, Mascaux C et al. Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer. Ann Oncol 2013;24:1170-1179.
14. Ahmadzadeh M, Johnson LA, Heemskerk B et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 2009;114:1537-1544.
15. Akbay EA, Koyama S, Carretero J et al. Activation of the PD-1 pathway contributes to immune escape in EGFRdriven lung tumors. Cancer Discov 2013;3:1355-1363.
16. Zhang Y, Huang S, Gong D et al. Programmed death-1 upregulation is correlated with dysfunction of tumorinfiltrating CD8+ T lymphocytes in human non-small cell lung cancer. Cell Mol Immunol 2010;7:389-395.
17. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-2454.
18. Brahmer JR, Tykodi SS, Chow LQ et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455-2465.
19. Ribas A. Tumor immunotherapy directed at PD-1. N Engl J Med 2012;366:2517-2519.
20. Yang CY, Lin MW, Chang YL et al. Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes. Eur J Cancer 2014;50:1361-1369.
21. Azuma K, Ota K, Kawahara A et al. Association of PDL1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer. Ann Oncol 2014;25:1935-1940.
22. D'Incecco A, Andreozzi M, Ludovini V et al. PD-1 and PD-L1 expression in molecularly selected nonsmall-cell lung cancer patients. Br J Cancer 2014;112: 95-102.
23. Travis WD, Brambilla E, Noguchi M et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011;6:244-285.
24. Gadiot J, Hooijkaas AI, Kaiser AD et al. Overall survival and PD-L1 expression in metastasized malignant melanoma. Cancer 2011;117:2192-2201.
25. Velcheti V, Schalper KA, Carvajal DE et al. Programmed death ligand-1 expression in non-small cell lung cancer. Lab Invest 2014;94:107-116.
26. Chen BJ, Chapuy B, Ouyang J et al. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res 2013;19:3462-3473.
27. Tsao MS, Liu N, Chen JR et al. Differential expression of Met/hepatocyte growth factor receptor in subtypes of non-small cell lung cancers. Lung Cancer 1998;20: 1-16.
28. Park HS, Lee JK, Kim DW et al. Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients. Lung Cancer 2012;77:288-292.
29. Jeon YK, Sung SW, Chung JH et al. Clinicopathologic features and prognostic implications of epidermal growth factor receptor (EGFR) gene copy number and protein expression in non-small cell lung cancer. Lung Cancer 2006;54:387-398.
30. Go H, Jeon YK, Park HJ et al. High MET gene copy number leads to shorter survival in patients with nonsmall cell lung cancer. J Thorac Oncol 2010;5:305-313.
31. Kim YT, Seong YW, Jung YJ et al. The presence of mutations in epidermal growth factor receptor gene is not a prognostic factor for long-term outcome after surgical resection of non-small-cell lung cancer. J Thorac Oncol 2013;8:171-178.
32. Kundel HL, Polansky M. Measurement of observer agreement. Radiology 2003;228:303-308.
33. Zhang Y, Wang L, Li Y et al. Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma. Onco Targets Ther 2014;7: 567-573.
34. Marzec M, Zhang Q, Goradia A et al. Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proc Natl Acad Sci USA 2008;105:20852-20857.
35. Wilke CM, Wei S, Wang L et al. Dual biological effects of the cytokines interleukin-10 and interferon-gamma. Cancer Immunol Immunother 2011;60:1529-1541.
36. Parsa AT, Waldron JS, Panner A et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med 2007;13: 84-88.
37. Jiang X, Zhou J, Giobbie-Hurder A et al. The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition. Clin Cancer Res 2013;19:598-609.
38. Gelsomino F, Facchinetti F, Haspinger ER et al. Targeting the MET gene for the treatment of nonsmall-cell lung cancer. Crit Rev Oncol Hematol 2014; 89:284-299.
39. Engelman JA, Zejnullahu K, Mitsudomi T et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316:1039-1043.
40. Konishi J, Yamazaki K, Azuma M et al. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res 2004;10:5094-5100.
41. Mu CY, Huang JA, Chen Y et al. High expression of PDL1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med Oncol 2011;28:682-688.
42. Chen YB, Mu CY, Huang JA. Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: A 5-year-followup study. Tumori 2012;98:751-755.
43. Soria JC, Cruz C, Bahleda R et al. Clinical activity, safety and biomarkers of PD-L1 blockade in non-small cell lung cancer (NSCLC): Additional analyses from a clinical study of the engineered antibody MPDL3280A (anti-PDL1). Eur J Cancer 2013;49: Abstract 3408.
44. Azuma T, Yao S, Zhu G et al. B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood 2008;111: 3635-3643.
45. Liu H, Zhang T, Ye J et al. Tumor-infiltrating lymphocytes predict response to chemotherapy in patients with advance non-small cell lung cancer. Cancer Immunol Immunother 2012;61:1849-1856.
46. Hamanishi J, MandaiM, IwasakiMet al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci USA 2007;104:3360-3365.
47. Al-Shibli KI, Donnem T, Al-Saad S et al. Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin Cancer Res 2008;14: 5220-5227.
48. Badoual C, Hans S, Merillon N et al. PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res 2013;73:128-138.
49. Hsu MC, Hsiao JR, Chang KC et al. Increase of programmed death-1-expressing intratumoral CD8 T cells predicts a poor prognosis for nasopharyngeal carcinoma. Mod Pathol 2010;23:1393-1403.